Jnj Stock Rises on Profit Beat as Stelara Weakness Tests J&J’s 2026 Outlook
Jnj stock is getting a fresh read after Johnson & Johnson delivered a first-quarter earnings beat and lifted its full-year forecast, even as Stelara sales fell sharply. The result is a split-screen quarter: one side shows stronger demand for cancer and psoriasis medicines, while the other shows how fast a former blockbuster can lose momentum after patent protection fades. The company’s numbers suggest that product mix, not just total sales, is now shaping the story investors are watching most closely in Eastern Time trading.
Profit beat, but the mix matters more
Johnson & Johnson said first-quarter revenue reached $24. 1 billion, up nearly 10% from a year earlier and above analysts’ estimate of $23. 6 billion. Adjusted earnings came in at $2. 70 per share, also ahead of consensus expectations of $2. 66. Those results would normally be enough to dominate the narrative, but the quarter’s deeper message is that Jnj stock is being judged on whether newer products can keep replacing older revenue streams as the portfolio shifts.
Stelara remains the clearest example of that pressure. Once a drug that topped $10 billion in annual sales at its peak, it is now facing biosimilar competition after losing patent protection last year. Sales fell about 60% from a year earlier to $656 million. That decline did not overwhelm the quarter, but it showed how quickly a product can move from growth engine to drag when generic-style competition enters the market.
Darzalex and Tremfya carry the quarter
The company’s cancer and immunology drugs provided the offset. Darzalex, a blood cancer therapy launched in 2015, generated $4. 0 billion in quarterly sales, well above analysts’ expectations of $3. 4 billion. Tremfya, which treats psoriasis and inflammatory bowel diseases, brought in $1. 6 billion, also ahead of expectations of $1. 2 billion. Chief Financial Officer Joseph Wolk said many patients are choosing other treatments rather than moving to biosimilars, adding that the company is seeing increased share in Tremfya and expects a similar pattern in its new oral offering Icotyde, which was approved in March.
That is the key analytical point behind the quarter: the company is not simply replacing lost Stelara revenue with one product. It is showing a broader shift in demand across its portfolio. In that context, Jnj stock is being supported less by one standout medicine than by a cluster of products that can absorb the decline of a former giant.
Guidance, pricing pressure, and what investors are weighing
Johnson & Johnson raised its full-year 2026 revenue forecast to a midpoint of about $100. 8 billion, just above Wall Street’s estimate of $100. 6 billion. It also lifted its adjusted earnings outlook to $11. 55 per share at the midpoint, roughly in line with current expectations. For investors, that matters because guidance signals management confidence that the current product mix can sustain growth even as Stelara weakens further.
The company also remains part of a group of top global drugmakers that have agreed to most-favored-nation drug pricing deals with the Trump administration. Those deals would lower U. S. drug prices to match those in other developed countries in exchange for tariff relief. President Donald Trump has asked Congress to codify the agreements through legislation, but Wolk said the company believes that would be bad policy. His concern is straightforward: if pricing is locked in too tightly, access and innovation may suffer.
What the quarter means beyond one trading session
Quarterly sales for the medical technology business rose 7. 7% to $8. 6 billion, matching analysts’ expectations. Shares were marginally down premarket, even after having risen 15% so far this year. That reaction suggests investors are already looking past the headline beat and toward the durability of the company’s next phase.
For now, the market story is less about one quarter than about whether the company can keep converting scientific momentum into revenue resilience. If cancer medicine growth holds, and if the new oral offering gains traction, Jnj stock may continue to look insulated from the Stelara reset. The open question is whether that transition can stay ahead of pricing pressure, biosimilar competition, and the expectations now built into the forecast.
